For the past 128 years, a hospital tucked away on what was once a rural farm in Johannesburg East has been fighting to turn the tables on a disease that has plagued humankind for millennia. Ufrieda Ho has the latest in Spotlight’s special series of ‘Hospital Histories’.
In 1984, the then-head of Brooklyn Chest TB Hospital, Dr David Jenkin lamented inadequate services for TB patients, writing that “it is unflattering to realize that only war and pestilence appear able to bring more beds for TB sufferers”. Almost 40 years later, despite major scientific advances, TB hospitals like Brooklyn Chest remain important for treating complicated forms of the disease, where specialised healthcare staff can monitor medication interactions and side-effects. Biénne Huisman takes a look back at the hospital’s 151-year history and the difference it is making in the lives of children with TB today.
The uptake and continuation of tuberculosis preventive therapy were much higher when it was provided through a community-based model compared to the standard clinic-based model, a study conducted in KwaZulu-Natal found. Elri Voigt unpacks the study findings, which were recently presented at the Conference for Retroviruses and Opportunistic Infections in Seattle, USA.
The current treatment for drug-susceptible tuberculosis (TB) used in South Africa last for six months, effectively cures TB and is dirt cheap. Two studies in recent years have shown that TB can be cured in four or in some cases even two months, but price and other complications make these treatments tricky to implement. At a conference in Seattle last week, a major trial of an alternative four-month treatment reported disappointing findings. Elri Voigt unpacks the latest findings and asks what the prospects now are for shortening TB treatment.
New research shows a quick-dissolving, rectal suppository designed to prevent HIV infection is safe, although its efficacy remains to be tested in clinical trials, some of which will be conducted in South Africa. Still, the findings released late Tuesday could herald the start of a new “take as needed” era in HIV prevention.
Antibiotics play a vital role in the management of bacterial infections, reducing illness, and preventing many deaths. A 2011 report from the UK estimated that they have increased life expectancy by 20 years. However, the extensive use of antibiotics has resulted in drug resistance that threatens to reverse their life-saving power and if the situation is not reversed, it has been estimated that by 2050 as many as 10 million people will die annually of drug-resistant infections. Tiyese Jeranji looks at how antimicrobial resistance plays out in South Africa and the role of pharmacists in the fight against it.
Some cases of tuberculosis (TB) can be successfully treated in as little as two months – a third of the current standard of six months. This is according to early findings from the landmark TRUNCATE TB trial presented at last week’s Union World Conference on Lung Health. Elri Voigt reports.
Professor Wendy Stevens believes ‘completely in the honesty of science’ and this, she says, has landed her in the naughty corner many times throughout her career. Biénne Huisman spoke to Stevens – a global leader in HIV and TB laboratory medicine about her career, what you choose when science and politics collide, and the value of swimming upstream.
Professor Resia Pretorius and her colleagues at the University of Stellenbosch are at the cutting edge of research into one of the most likely causes of long COVID – inflammatory microclots. Adele Baleta spoke to Pretorius about their work.
Tuberculosis can be challenging to diagnose in children, especially very young children. This is because it is difficult for them to cough up the sputum required by gold standard molecular tests and because they have fewer TB organisms in their sputum than adults. X-ray screening may be part of the solution, but it has shortcomings. Following some interesting recent study findings, Tiyese Jeranji asks what role lung ultrasound may have in improving TB detection in kids.
Indications are that the virus that causes COVID-19 is going to continue evolving and escaping the protection against infection people already have. Researchers are working on next-generation vaccines tailored to fight off specific versions of the virus, like the Omicron sub-lineages BA.4 and BA.5. But can these new vaccines be tested and produced fast enough to keep up with the rapidly changing virus? Aisha Abdool Karim asked some local experts.
Omicron and its sub-variants have been dominating new surges of SARS-CoV-2 infections around the world and were behind South Africa’s fifth wave. The BA.4 and BA.5 sub-lineages unveiled yet more surprises about the evasive nature of these ever-emerging forms of SARS-CoV-2. They also hold clues for what to expect next and how to prepare. Aisha Abdool Karim reports.
